Vitality Watch

Dossier clinicaltrials trial early 25-sep-2026
Small or early-phase human trial or pilot study

Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome

Key claim: A Phase I study is testing the safety and tolerability of allogeneic umbilical cord mesenchymal stem cells (HeXell-2020) in elderly subjects with mild to moderate frailty syndrome.

Abstract

This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.

HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

Why this matters

A Phase I study is testing the safety and tolerability of allogeneic umbilical cord mesenchymal stem cells (HeXell-2020) in elderly subjects with mild to moderate frailty syndrome.

Source

Link

Briefing card

Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
Stage: trial early · clinicaltrials · 25-sep-2026

A Phase I study is testing the safety and tolerability of allogeneic umbilical cord mesenchymal stem cells (HeXell-2020) in elderly subjects with mild to moderate frailty syndrome.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07144072

build build 880 · 2bcef25 · 2026-11-18